For type 2 diabetes mellitus. ANDA 76756, held by Nostrum Pharms LLC. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 76756 (Metformin Hydrochloride), held by Nostrum Pharms LLC, was first approved by FDA on Jul 26, 2006, with 4 approved supplements and 0 published complete response letters.
Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 26, 2006 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride750MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 16Labeling · Standard review | Approved | None posted |
| Nov 5, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 5, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 12, 2011 | Supplement 1Manufacturing | Approved | None posted |
| Jul 26, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters